Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS)
Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS)
复制标题
DOI：
10.1093/arclin/act021
复制
发表时间：
2013-06-01
影响因子：
2.6
通讯作者：
Maruff, Paul
中科院分区：
文献类型：
--
作者：
Lim, Yen Ying;Jaeger, Judith;Maruff, Paul
阿尔茨海默病（AD）的大型前瞻性研究试图了解AD的病理演变和可能影响疾病进展速度的因素。认知变化率的估计值可用于12个月或24个月，但不适用于较短的时间范围（例如，3或6个月）。大多数寻求减少或改善AD症状的临床药物试验已经进行了12周或24周的时间。因此，我们的目的是表征一组健康老年人，遗忘型轻度认知障碍（aMCI）的成年人，和AD的成年人在CogState电池的测试在短的测试间隔的性能。这项研究招募了105名健康老年人，48名aMCI成人和42名来自澳大利亚成像，生物标志物和生活方式研究的AD成人，并在3个月内每月进行CogState电池测试。CogState电池的测试显示高testretest的可靠性和稳定性，在所有临床组的参与者进行了评估超过3个月。当在基线时考虑时，CogState成套测试能够检测AD相关的认知障碍。这些数据提供了健康老年人、aMCI成人和AD成人中每个认知测试的可靠性、稳定性和变异性的重要估计。这可能会用于为临床试验中认知变化的未来估计提供信息。
Large prospective studies of Alzheimers disease (AD) have sought to understand the pathological evolution of AD and factors that may influence the rate of disease progression. Estimates of rates of cognitive change are available for 12 or 24 months, but not for shorter time frames (e.g., 3 or 6 months). Most clinical drug trials seeking to reduce or modify AD symptoms have been conducted over 12- or 24-week periods. As such, we aimed to characterize the performance of a group of healthy older adults, adults with amnestic mild cognitive impairment (aMCI), and adults with AD on the CogState battery of tests over short testretest intervals. This study recruited 105 healthy older adults, 48 adults with aMCI, and 42 adults with AD from the Australian Imaging, Biomarkers, and Lifestyle study and administered the CogState battery monthly over 3 months. The CogState battery of tests showed high testretest reliability and stability in all clinical groups when participants were assessed over 3 months. When considered at baseline, the CogState battery of tests was able to detect AD-related cognitive impairment. The data provide important estimates of the reliability, stability, and variability of each cognitive test in healthy older adults, adults with aMCI, and adults with AD. This may potentially be used to inform future estimates of cognitive change in clinical trials.